US Patent

US8865211 — Bioadhesive drug formulations for oral transmucosal delivery

Method of Use · Assigned to AcelRx Pharmaceuticals Inc · Expires 2027-01-05 · 1y remaining

Vulnerability score 80/100 Vulnerable — likely target for IPR or design-around

What this patent protects

This patent protects bioadhesive drug formulations for delivering a drug to the oral mucosa, specifically for use with a subject.

USPTO Abstract

Bioadhesive drug formulations that adhere to an oral mucosal membrane of a subject are provided together with single dose applicators and devices for delivering the drug formulations to the oral mucosa, and methods for using the same.

Drugs covered by this patent

sufentanil-citrate (SUFENTANIL CITRATE)

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-1351`	—	sufentanil-citrate

Patent Metadata

Patent number: US8865211
Jurisdiction: US
Classification: Method of Use
Expires: 2027-01-05
Drug substance claim: No
Drug product claim: No
Assignee: AcelRx Pharmaceuticals Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.